Skip to main content

What the FDA labels say about taking them together

Meloxicam and warfarin

Meloxicam's FDA label of January 29, 2026 names warfarin in its drug interactions section; warfarin's label does not name meloxicam itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The meloxicam label: “Meloxicam and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of meloxicam and anticoagulants have an increased risk of serious bleeding compared to the use of either drug …”

Check it at the source: the meloxicam FDA label on DailyMed (effective January 29, 2026, PD-Rx Pharmaceuticals, Inc.); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).

What does the meloxicam label say about warfarin?

Meloxicam label, drug interactions

Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.

Meloxicam label, warnings and precautions

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk.

Qamzova label (Nanjing Delova Biotech Co., Ltd., July 16, 2026), drug interactions

Drugs That Interfere with Hemostasis Clinical Impact: Meloxicam and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of meloxicam and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. … Intervention: Monitor patients with concomitant use of QAMZOVA with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [ see Warnings and Precautions () ].

Source: FDA drug label (Qamzova, NDA217593), Nanjing Delova Biotech Co., Ltd., effective July 16, 2026 (SPL set 385fd779-1be1-49ae-8213-750b96ecc997), via openFDA

Source: FDA drug label (Meloxicam, NDA021530), Emerald Therapeutics, LLC, effective May 29, 2026 (SPL set 55af77dd-2abc-49a6-990c-399d5a5e7a91), via openFDA

Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed

What does the warfarin label say about meloxicam?

Warfarin's label does not name meloxicam itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):

Warfarin label, drug interactions

Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram …

Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

43Meloxicam generic labelers
19Warfarin generic labelers
MeloxicamWarfarin
Labeled forOsteoarthritis, Rheumatoid arthritis, PainBlood clots (DVT and PE), Atrial fibrillation
Boxed warningYesYes
Pharmacy cost (NADAC)$0.0166 per tablet 7.5 mg tablet$0.093 per tablet 2 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?